CD274 and neoplasm: Immunohistochemical (IHC) PD-L1 expression is currently the only clinically approved predictive biomarker for checkpoint inhibition in TNBC and it has been suggested to implement combined evaluation of PD-L1 and stromal tumor infiltrating lymphocytes (TILs) as a more comprehensive biomarker for patient selection [10].